Table 1. Patient characteristics and in... | American Society of Hematology

Table 1.

Patient characteristics and in vitro sensitivity of B-cell chronic lymphocytic leukemia cells to KRN5500

Patient	Modified Rai stage	Previous treatment	4-hour LC₅₀ KRN5500, μM	24-hour LC₅₀ KRN5500, μM	96-hour LC₅₀ KRN5500, μM
1	IR	None	22.46	1.89	0.44
2	HR	C, C + Pent + Theo	0.21	0.91	0.09
3	HR	Flu	0.16	0.02	0.027
4	HR	None	1.12	0.22	0.26
5	HR	C + P, Flu, 2CDA	0.18	0.05	0.05
6	IR	C + P	0.45	0.13	0.123
7	IR	None	0.94	0.24	0.175
8	IR	None*	0.14	0.05	0.024
9	IR	None*	0.19	0.07	0.052
10	IR	None*	0.11	0.028	0.024
11	IR	None	1.55	0.36	0.260

Patient	Modified Rai stage	Previous treatment	4-hour LC₅₀ KRN5500, μM	24-hour LC₅₀ KRN5500, μM	96-hour LC₅₀ KRN5500, μM
1	IR	None	22.46	1.89	0.44
2	HR	C, C + Pent + Theo	0.21	0.91	0.09
3	HR	Flu	0.16	0.02	0.027
4	HR	None	1.12	0.22	0.26
5	HR	C + P, Flu, 2CDA	0.18	0.05	0.05
6	IR	C + P	0.45	0.13	0.123
7	IR	None	0.94	0.24	0.175
8	IR	None*	0.14	0.05	0.024
9	IR	None*	0.19	0.07	0.052
10	IR	None*	0.11	0.028	0.024
11	IR	None	1.55	0.36	0.260

IR indicates intermediate risk; HR, high risk; C, chlorambucil; Pent, pentostatin; Theo, theophylline; Flu, fludarabine; P, prednisone; 2CDA, cladribine.

Active disease as required treatment within 6 months of donating cells.

View Large

This Feature Is Available To Subscribers Only